Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to disseminate knowledge & skills of Acute Cardiovascular Care.
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission is to promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our mission is to reduce the burden of cardiovascular disease in Europe through percutaneous cardiovascular interventions.
Our mission is to improve the quality of life of the population by reducing the impact of cardiac rhythm disturbances and reduce sudden cardiac death.
Our mission is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
The ESC Working Groups' goal is to stimulate and disseminate scientific knowledge in different fields of cardiology.
The ESC Councils' goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
Dr. Volkmar Falk,
The session started with Jean-Francois Avierinos who first explored the pathophysiology of secondary mitral insufficiency. He explained the different mechanisms leading to secondary MI and discussed the indication for repair versus replacement based on the extent of subvalvular involvement. Patient prosthesis mismatch continues to be a matter of lively debates. In his elegant talk Julien Magne gave a definition of PPM and discussed the implication for both aortic and mitral valve replacement. Severe PPM has an impact on survival and should be avoided whenever feasible. Michael Borger gave an overview about various mitral valve repair techniques for degenerative mitral valve insufficiency with special focus on the results with the Loop-technique. He also demonstrated different repair techniques for Barlows disease and discussed the contemporary outcomes of mitral valve repair. In high volume centers mortality is less than 1% and repair rates exceed 90%. Long term freedom from reoperation or >II+ MI after 10 years is currently in the range of >90% independent of the underlying pathology (posterior, anterior or bileaflet prolapse). The timing for mitral valve repair in asymptomatic patients is a matter of continuing debate. The so called “watchful waiting” strategy is favoured by some whereas early surgery is preferred by others. Michele De Bonis from Milan presented the evidence that led to the current guideline recommendations for mitral valve repair in degenerative disease, that gives indications also for patients with asymptomatic severe MI. In addition he presented evidence for other subtle changes such as an increase in left atrial dimension that may have a negative prognostic impact in patients left untreated. Early intervention for asymptomatic patients especially is however only justifiable if excellent operative results can be accomplished.
Controversies in valvular heart surgery
© 2017 European Society of Cardiology. All rights reserved